绿叶制药(02186.HK) 公布，集团的1类创新药LY03021已获得中国国家药监局药品审评中心批准开展临床试验，拟用于治疗抑郁症。LY03021基于集团新分子实体/新治疗实体技术平台自主开发，是全新的三靶点作用机制抗抑郁药物，具有同类首创(First-in-Class)的潜质。据公司所知，目前尚未检索到相同机制的产品在研。(gc/da)(港股报价延迟最少十五分钟。沽空资料截至 2024-11-08 16:25。)
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.